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Surm-nary 
Immunization  of mice with  tumors  genetically engineered to  express the B7  costimulatory 
molecules amphfies the antitumor inunune response mediated by CD8 + cytolytic T  lympho- 
cytes (CTL). In this report, we examined the effect ofB7-CD28 costimulation on the hierar- 
chy of tumor epitopes. Using a combination of affinity chromatography/reversed-phase high 
performance liquid chromatography and CTL cloning, we show that major histocompatibility 
complex (MHC)  class l  molecules from EL4 lymphoma cells can present at least six distinct 
CTL epitopes presented by MHC class I molecules. Nevertheless, mice immunized with wild- 
type B7-negative EL4 cells develop CTL only to one immunodominant epitope. In contrast, 
immunization with B7-transduced EL4 cells led to not only the amplification of the CTL re- 
sponse to this immunodominant epitope, but also  to the recognition of five otherwise silent 
subdominant  epitopes.  The  adoptive  transfer  of a  CTL  clone  against  such  a  subdominant 
epitope cured mice bearing EL4 lymphoma growing as an ascites tumor. The fact that CTL re- 
sponse can be spread to normally silent epitopes as a result ofB7-CD28 costimulation suggests 
a novel approach to manipulate the hierarchy ofCTL epitopes and offers an opportunity to ex- 
plore novel targets for T  cell-mediated cancer therapy. 
F 
%r an efficient T  cell activation to occur, both a specific 
signal  dehvered through  the  TCR  by antigenic pep- 
tides-MHC and a costimulatory signal  mediated by mole- 
cules  of the  B7  family through  their ligand  CD28  on  T 
cells are required (1, 2). TCR signaling by antigen without 
proper costimulation may cause antigen-specific unrespon- 
siveness  (3).  By transfer of the  B7-1  or  B7-2  genes into 
mouse tumor cells, protective and sometimes curative im- 
munity  against  untransfected  wild-type  (wt) 1 tumors  has 
been generated in several mouse models (4-7). Immune re- 
sponses amplified by B7 costimulation are mainly mediated 
by CD8 + CTL (8, 9), although CD4 + T cells may also play 
a role in some tumor models (10,  11). 
Many potential antigenic peptides are presented by a tu- 
mor or virus,  but  only a  few immunodominant epitopes 
elicit a response whereas others are silent (12,  13).  There 
are several possible mechanisms for this epitope hierarchy. 
The "hole" in the T  cell repertoire may exist because of a 
deletion ofT cell clones in the thymic or peripheral devel- 
opment (13). In addition, there is growing evidence that si- 
~Abbreviations used in this paper: BC-SC, bulk cultured spleen cells; TAP, 
transporter-associated  protein; wt, wild type. 
lent  epitopes  are  produced  with  very low  efficiency by 
normal routes of antigen processing and presentation (14- 
16).  Proteasome-mediated proteolysis  may  contribute  to 
the selection process by either destroying the  epitopes or 
changing the cleavage pattern (17).  The strong MHC class 
I-binding of most immunodominant epitopes argues that a 
peptide's affinity plays a role in determining its immunoge- 
nicity, although not all strongly binding peptides  are im- 
munodominant (18-20). 
The beneficial effect of B7-CD28 costimulation on the 
immune response to tumors could be caused by an expan- 
sion of CTL clones recognizing immunodominant tumor 
antigens  due to  the increased production of lymphokines 
(21)  which prevents T  cell anergy caused by exposure to 
antigen in the absence of a second signal  (22,  23).  How- 
ever,  costimulation  by  B7-CD28  interaction  may  also 
make possible the recognition of additional, otherwise si- 
lent antigens by either increasing the tumor-CTL interac- 
tion or by amplifying the signaling to TCR. To be able to 
distinguish between these possibilities,  we have employed a 
previously studied mouse EL4 lymphoma model (24).  The 
EL4 lymphoma is highly tumorigenic in syngeneic C57BL/6 
mice  and  does  not  express  molecules  of the  B7  family 
whereas it expresses a high level of MHC class I molecules. 
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munization of syngeneic mice with wt EL4 cells induces a 
weak CTL response and, at best, a partial protective immu- 
nity against challenge with wt tumor  (24-26),  immuniza- 
tion with EL4 cells transduced with a recombinant retrovi- 
ms  containing  mouse  B7-1  cDNA  (B7 +  EL4)  induces  a 
strong protective immunity  against wt  tumor.  Moreover, 
mice bearing a small established s.c. EL4 lymphoma can be 
cured by repeated injection with B7 § EL4 cells (24). 
In the current study, we first established a panel of CTL 
clones  and  long-term  CTL  hnes  from  mice  immunized 
with B7 § EL4 cells and used them as probes to identify the 
CTL epitopes presented by EL4 cells. The peptides associ- 
ated with MHC  class I molecules of EL4 cells were isolated 
and  subjected to  HPLC  fractionation.  Individual peptides 
were then loaded into transporter-associated protein (TAP)- 
deficient RMA-S  cells to  examine the reactivity of CTL. 
We demonstrate that at least six distinct CTL epitopes are 
naturally processed and  presented by the EL4  lymphoma. 
Using this system, we were able to trace the activation sta- 
tus  of CTL  to  the  corresponding  epitopes  in  polyclonal 
populations, and to study the effect of B7-CD28  costimu- 
lation  in  the  hierarchy  of tumor  epitopes  recognized by 
CD8 + CTL. 
Materials and Methods 
Mice and Cell Lines.  Female  C57BL/6  mice,  4-8  wk  old, 
were purchased from Taconic Farms, Inc.  (Germantown,  NY). 
MHC class lI-deficient female C2D mice (27), which originated 
from C57BL/6  mice, were purchased from GenPharm Interna- 
tional (Mountain View, CA). The EL4 and TIMI.4 lymphomas 
are ofC57BL/6 (H-2  b) origin, the P815 mastocytoma is of  DBA/2 
(H-2  a) origin, and the NK cell-sensitive lymphoma YAC-1 is of 
A/Sn origin. The B7 + EL4 line had been generated previously in 
our laboratory by infection of EL4 cells with pLXSN recombi- 
nant retrovirus containing murine B7-1 cDNA (24). The mock.EL4 
line was derived similarly, but infected with parental retrovirus 
(24).  The  P815.K  b and P815.D b clones are derived from P815 
cells  transfected  with  pBR327  plasmids  containing  H-2K  b  or 
H-2D  b genomic  DNA  (28),  respectively. RMA-S  lymphoma, 
which is deficient in the TAP-2 peptide transporter (29),  is of 
C57BL/6 (H-2  b) origin. All lines were examined in a mouse anti- 
body production test (Microbiological  Associates, Inc., R_ockville, 
MD) and shown to be free of Mycoplasma and the following vi- 
ruses: Sendai pneumonia vires, mouse hepatitis virus, pneumonia 
virus of mice, reovirus type 3, mouse adenovirus, Theiler's mouse 
encephalitis virus, ectrometia virus, minute virus of mice, poly- 
oma virus, lactic dehydrogenase virus, epizootic diarrhea of infant 
mice, mouse thymic virus, Hantaan virus, K virus, mouse orphan 
parvo virus, mouse cytomegalovirus, and lymphocytic choriomen- 
mgms wrus. 
Generation and Assay of CTL.  Methods for the immunization 
and assay ofEL4-reactive CTL in bulk-cultured spleen cells (BC- 
SC) have been described (30). Briefly, mice were injected subcu- 
taneously with live B7- EL4 (wt or mock transduced) or hve B7 + 
EL4  cells  at  5  ￿  104/mouse  or,  in some  experiments, at  106/ 
mouse.  10-14 d later, spleen cell suspensions were prepared and 
cocultivated for 5-7 d at 5 ￿  106/well with ~-irradiated (10,000 
rad)  B7 §  EL4  cells  (10S/well)  in  24-well plates.  BC-SC  were 
then tested in a standard 4-h SlCr release assay as described. In six 
experiments, irradiated B7-  EL4  cells  were  injected at  3-5  ￿ 
106/mouse s.c. or i.p. and the mice were boosted twice with the 
same number of cells at 2-wk intervals. All immunization meth- 
ods  gave  similar results.  In  cell depletion assays, BC-SC  from 
mice immunized with either B7-  EL4  or B7 §  EL4  were pre- 
treated as described (30) with mAbs to murine TCR.-cx/~ (H57- 
597),  TCR-"//~  (GL3)  (PharMingen,  San  Diego,  CA),  CD4 
(GK1,5), CD8 (HO2.2), or human MHC class II (L227) as a con- 
trol at 20 t~g/ml plus rabbit complement before the CTL assay. 
Generation of CTL Lines and Clones.  To  generate  long-term 
CTL lines, '~1-5  ￿  los/well BC-SC were restimulated every 
7-14 d with  10S/well irradiated (10,000  rad) B7 + EL4 cells to- 
gether with 5  ￿  106 irradiated (3,000 rad) syngeneic spleen cells 
in the presence of human recombinant IL-2 at 10 U  (Cetus)/ml 
(1 cetus unit =  6 international units). CTL clones were obtained 
by bruiting dilution of CTL lines in 96-well plates. 
Isolation  and  Purification of MHC  Class 1-associated Peptides. 
Purified peptides were prepared from MHC proteins as described 
(31),  with  modifications. Briefly,  20-40  g  cell pellets  ("-,2.7- 
5.5 ￿  10 w) of cultured B7- or B7 § EL4 cells were washed with 
PBS  and mixed with  an  equal  volume  of solubilization buffer 
containing 2% NP-40, 0.8 M  NaC1,  20 mM Na2EDTA, 2 mM 
PMSF, 100 ~M iodoacetamide, 10 I~g/ml pepstatin A, 10 ~g/ml 
leupeptin, and 5 ~g/ml aprotinin in PBS. The cells were gently 
agitated for 30 rain at 4~  nuclei removed by low-speed centrif- 
ugation at 1,500 g for 5 nfin at 4~  and the total protein concen- 
tration adjusted to 2 mg/ml. The cell lysate was clarified by cen- 
trifugation  at  100,000  g  for  90  rain.  The  H-2K  b and  H-2D  b 
complexes were then purified by immunoaffinity chromatogra- 
phy using mAb (the Kb-specific mAb, Y-3, and the Db-specific 
mAb,  28-14-8S)  coupled  to  CNBr-activated  Sepharose  4B. 
MHC  complexes were eluted with 1% TFA. Peptides were re- 
covered by ultrafiltration using a stirred cell (Amicon Corp., Bev- 
erly, MA) with a 10,000  molecular weight cut-offand were con- 
centrated by vacuum centrifugation. Peptides were purified on a 
narrow-bore HPLC  system (model  130A;  Apphed Biosystems, 
Inc., Foster City, CA) using a 100-mm column (model C18; Vy- 
dac, Hesperia, CA) at a flow rate of 100 Ixl/min at 40~  Linear 
acetonitrile gradients from solvent A  (0.1%  TFA) to  solvent B 
(0.085% TFA in acetonitrile) were used for elution. 
Peptide Sensitization of RMA-S Cells.  Individual peptide frac- 
tions from B7-  or B7 §  EL4 cells were reconstituted in 200  Ixl 
PBS and t% aliquots were used for each well. For peptide sensiti- 
zation, RMA-S cells were preincubated at 22~  for 48 h, labeled 
with 51Cr at 22~  for 2 h, incubated with eluted peptides in 96- 
well V-shaped plates at 37~  for 1.5  h,  and the cells were sub- 
jected to a 4-h S~Cr release assay. 
Animal Studies.  Our method for in vivo depletion of T  cell 
population has been described (8). Briefly, mice were injected in- 
traperitoneally twice with purified mAb to CD4 (GK1.5) or CD8 
(2.43) at 1 rag/mouse on the day of and 14 d after tumor inocula- 
tion. Subsequently, the mice were injected on the shaved back 
with 5  ￿  104 B7 + EL4 cells. They were killed 4-5 wk later and 
spleen  cell suspensions were  prepared and  subjected to  FACS 
analysis to determine the efficiency of depletion (8). For blocking 
of the B7-CD28 interaction in vivo, the mice were injected with 
5  ￿  104 B7 + EL4 cells that had been premixed with 50  p,g of 
murine CTLA41g (32).  CTLA4Ig treatment was continued for a 
total of 2 wk by i.v. injection every other day at 50 p,g per treat- 
ment.  Mice  treated with  an  equal  amount  of mAb to  human 
CD5  (clone  10.2)  were  used  as  controls.  Tumor  growth  was 
monitored weekly as described (8). For adoptive immunotherapy, 
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Results 
Costimulation by B7 of the Cytolytic T Cell Response to EL4 
Lymphoma.  We reported previously that EL4  cells trans- 
duced  with  a  recombinant  retrovirus  containing  murine 
B7-1  cDNA  lost  their  tumorigenicity in  syngeneic  mice 
and  induced  a  strong  CTL  response  (24).  To  determine 
which  T  cell  population  mediates  the  regression  of B7 + 
EL4, mice were treated with anti-CD4 or anti-CD8 mAbs 
to deplete different T  cell subpopulations, a procedure that 
removed >95% of the respective T  cell population without 
affecting other cells (8,  30).  As shown  in  Fig.  1 A,  treat- 
ment with  a  mAb to  CD8,  but not  to  CD4  or a  control 
mAb,  prevented  the  rejection of tumors  induced by B7 + 
EL4 cells, indicating that CD8 + CTL play a key role in B7- 
mediated tumor rejection in this system, similar to  others 
studied in the past  (8).  Treatment  with  CTLA4Ig,  which 
blocks  the  interaction  between  B7  and  CD28/CTLA-4 
(32),  abrogated the  regression of tumors  induced  by B7 + 
EL4  cells  (Fig.  1  B)  in  syngeneic mice.  Furthermore,  the 
CTL  activity  of BC-SC  against  EL4  from  mice  treated 
with CTLA4Ig was significantly decreased (Fig. 2 A), indi- 
cating that induction of CTL by B7 + EL4 cells was depen- 
dent on costimulation mediated by B7--CD28 interaction. 
The cytolytic activity of BC-SC from B7 + EL4-immu- 
nized mice appears to be restricted by MHC  class I mole- 
cules and specific for EL4 since CTL did not lyse the syn- 
geneic  lymphoma  TIMI.4,  the  allogeneic  mastocytoma 
P815, P815  cells transfected to express K b (P815.K  b) or D b 
(P815.Db),  or the NK-sensitive lymphoma YAC-1  (Fig. 2 
B).  Experiments  in  which  T  cell subsets  of BC-SC  were 
depleted with specific mAb to TCR-ot/[3  or ~//8 or to the 
CD4  or CD8  markers indicated that the  cytolytic activity 
was mediated by TCR+CD8 + o~/~ T  cells (Fig. 2  C). BC- 
SC  generated  from  wt  EL4-immunized  mice  had  similar 
characteristics  although  the  cytolytic  activity  was  much 
lower (Fig. 2, B and C). Taken together, the findings dem- 
onstrate that a BT-l-costimulated CD8 + CTL response can 
effectively destroy B7-  and  B7 +  EL4  lymphoma  cells in 
vitro and suggest that a  similar response is involved in tu- 
mor rejection. 
At least Six Distinct CTL Epitopes Are Presented by MHC 
Class I Molecules of wt EL4 Cells.  The strong CTL response 
detected  after  immunization  with  B7 §  EL4  cells  offered 
an opportunity  to  establish  long-term  CTL  cultures  and 
clones. A  panel of >50 CD3+CD8 + CTL clones and long- 
term CTL lines specific for EL4 cells was established from 
BC-SC orB7 § EL4-immunized mice. Similar to their par- 
ent BC-SC, these clones and lines lyse EL4 cells; their CTL 
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C57BL/6 mice, in groups of five, were administered intraperito- 
neally with  104 wt EL4 cells.  3  d  later, the mice were injected 
with 5 ￿  106 cells i.p. ofa T  cell clone C129 or the control CTL 
line followed on day 4 by injection of 1,500 U  of recombinant 
human IL-2 i.p. (Cetus Corp., Emeryville, CA) every day for 3 d. 
A  C57BL/6-derived anti-H-2  d CTL line was  generated as de- 
scribed (33)  and  used as  a  control.  The  mice were  monitored 
daffy for survival. 
-----O---. Control  mAb 
-~  Anti-CIM 
~-  Anti-CD8 
----o----  Control mAb 
--  CTLA4Ig 
Figure  1.  Regression of B7  + EL4 lymphoma is dependent  on  B7- 
costimulated CD8 + CTL. (A) Rejection orB7 + EL4 tumor is mediated 
by CD8 + T cells. C57BL/6 mice were injected with purified anti~CD4 
(GK1.5) or anti-CD8  (2.43) antibodies at  1 rag/mouse  i.p.  The same 
amount of  the anti-human CD5 antibody (10.2) was injected as a control. 
Mice were then inoculated with 5 ￿  10  4 B7 + EL4 cells s.c-, and tumor 
growth was assessed  as previously described (24). (/3) CTLA4Ig blocks re- 
jection of B7 + EL4 cells. Mice were injected on the shaved back with 
5 )<  104 B7 + EL4 cells that had been premixed with 50 I~g of murine 
CTLA41g. CTLA4Ig treatment was continued for a total of 2 wk by i.p. 
injection every other day at 50 Ixg/treatment. Mice treated with an equal 
amount  of mAb to human  CD5  (10.2) were  used as controls. Tumor 
growth was monitored weekly. 
activity appears to be restricted by either K b or D b mole- 
cules since inclusion ofmAbs specific to K b or D b (see Ma- 
terials and Methods)  in the  assay abrogated their cytolytic 
activity (data not shown). 
To  identify EL4  cell-derived antigens,  peptides associ- 
ated with MHC  class I  molecules were purified from  cell 
lysates of in vitro-cultured EL4 cells. Peptide--MHC class I 
complexes were purified by affinity chromatography using 
specific mAbs to either K 6 or D 6 and peptides were released 
by acid treatment and  quantitated by Edman  analysis. Se- 
quencing  of the peptide pools demonstrated  that  the  K b- 
associated peptides  were  eight  amino  acids long  and  the 
Db-associated peptides were nine amino acids long, sharing 
the  consensus  motit~  described  (31).  Incubation  of TAP- 
deficient R.MA-S cells at 37~  with H-2b-associated pep- 
tides prevented loss of both  K b and D b from  the cell sur- 
face,  as  detected  by  flow  cytometry  with  specific  mAbs 
(data not shown). 
Eluted  peptides  were  further  fractionated  by  reversed- 
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Figure 2.  Characteristics  of EL4-specific CTL. (A) C57BL/6 mice, in 
groups of five, were injected with 5 ￿  104 B7 + EL4 cells s.c. and then 
treated with CTLA4Ig at 50 ~g/mouse i.v. every other day for a total of 
2 wk. The same concentration  ofmAb to human CD5 (10.2) was used as 
a control. 3 wk after injection of 137 + EL4 cells, spleen cells were pre- 
pared and cocuhured with irradiated B7 + EL4 for 5 d. BC-SC were then 
tested for cytolytic  activity  on wt EL4 cells at the indicated  E/T ratios. (/3) 
The indicated  tumor lines  were labeled  with 250 p.Ci SlCr  at 37~  for 1 h 
and incubated at 5,000 cells/well  for 4 h with BC-SC from mice immu- 
nized with either wt EL4 (unfilled  bar) or B7 + EL40qlled  bar) at an E/T ra- 
tio  of 10:1  at 37~  The  supernatant was  collected and assayed in a 
gamma counter and the percent cytolytic  activity  was calculated. (C) BC- 
SC from mice immunized with either wt EL4 (unfilled bar) or B7 + EL4 
~qlled bar) were treated with mAbs to murine c~ TCP,. (H57-597), "/B 
TCt< (GL3), CD4 (GK1.5), or CD8 (HO2.2) at 20 p~g/ml  plus comple- 
ment, and then incubated  with SlCr-labeled  wt EL4 cells at E/T ratios of 
10:1. The same concentration of mAb to human MHC class II (L227; 
American Type Culture Collection,  Rockville,  MD) was used as a control. 
phase HPLC. The separation profiles of K b- (Fig. 3 A, left) 
and Db-derived peptides (Fig. 3  A,  right) are shown. Indi- 
vidual  peptide  fractions  were  then  loaded  to  sensitize 
RMA-S cells for CTL lysis  (Fig. 3  B).  Clone 4D9 reacted 
with P,.MA-S cells pulsed with K b fraction 9 and clone C12 
reacted with K b fractions 15 and 16, indicating that at least 
two  different Kb-restricted tumor peptides are  recognized 
by two different CTL clones. The CTL line C2D recog- 
nized D b fraction 8, indicating that this fraction contained a 
peptide not present in any of the other fractions. Similarly, 
clone  1A7  recognized D b fraction  14,  and clone  1B5  re- 
acted with D b fraction 9  only, whereas clone C129  recog- 
nized D b fractions 16. We conclude that at least six distinct 
peptides are  presented by MHC  class  I  molecules of EL4 
cells. 
Immunization  with  B7-  EL4  Cells  Cannot  Induce  CTL 
against  Subdominant  Tumor Antigens.  The  peptide-specific 
retention time of eluted peptides  (Fig. 3 A) allowed us to 
explore the specificity of individual T  celt clones in poty- 
clonal CTL. BC-SC generated from mice immunized with 
wt  EL4  or  mock.EL4  (both are  referred  to  as  B7-  EL4) 
were  tested  against RMA-S  cells  loaded  with  individual 
HPLC  fractions  (Fig.  4,  A-C).  BC-SC  from  B7-  EL4- 
immunized mice lysed wt EL4 cells (Fig. 4 A) and reacted 
to  Kb-derived peptides in HPLC fractions  16 significantly 
(Fig. 4 B) but did not react with Db-derived peptides (Fig. 
4  C).  These  results indicate that Kb-restricted peptides in 
fractions 16 may contain an immunodominant  peptide. The 
weaker CTL responses seen by immunizing  mice with B7- 
as compared to B7 + EL4 cells (see below) is not caused by 
insufficient exposure to tumor antigens since two different 
immunization methods,  multiple injections of large num- 
bers of irradiated EL4  cells or excision of growing tumor 
nodules (see  Materials and Methods), gave comparable re- 
sults. We conclude that immunization with B7- EL4 cells 
induced a  CTL response against an epitope presented by 
the H-2K  b molecule, which is, therefore, referred to as im- 
munodominant,  as  compared  to  subdominant  epitopes, 
which were not recognized by CTL raised with the wt EL4 
lymphoma. 
Activation  of CTL  against  Subdominant  Tumor Antigens  by 
Immunization with B7 + EL4 Cells.  An  increased  activity 
of costimulated CTL can be caused by (a) an increased ex- 
pansion of CTL clones against immunodominant  antigens; 
(b)  an activation of CTL  clones reactive  to  subdominant 
epitopes; and (c) a combination of these two events. As an 
attempt to examine these possibilities, the CTL activity of 
BC-SC  from  mice  immunized with  B7 +  EL4  cells  was 
tested against RMA-S cells loaded with individual peptide 
fractions. The costimulated BC-SC more efficiently lysed 
wt  EL4  cells  (Fig.  4  D)  and  P,  MA-S  cells  loaded  with 
HPLC fractions 9, 10, 15, and 16 of the K b peptides (Fig. 4 
E) as compared to noncostimulated BC-SC (Fig. 4  B), in- 
dicating  that  the  B7-CD28  interaction  expanded  CTL 
clones reactive  to  dominant EL4  antigens.  The  costimu- 
luted BC-SC displayed a strong CTL reactivity also against 
D b peptides in fractions 8, 9, and 14 and a weaker CTL re- 
sponse against D b peptides in fractions 11,  13,  and 16 (Fig. 
4 F). Since fractions 9 ofK  b and 8, 9, t4, and 16 of Db con  - 
tained  antigenically different peptides  (Fig.  3  /3)  that  did 
not induce any CTL activation when the  mice were  im- 
munized with B7-  EL4  cells, we  conclude that  immuni- 
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Figure  3.  CTL  epitopes in  HPLC-fraction- 
ated  peptides  from EL4  cells. (A)  Reversed- 
phase HPLC  separation of K b- and Db-associ - 
ated  peptides  from EL4.  Peptides  eluted  from 
MHC  of wt EL4  cells were chromatographed 
on a 100-ram C18 Vydac column. Elution pat- 
terns  of (left) 1,600  pmol  K  b peptides;  (right) 
1,620  pmol D b peptides from a 27-g (N1.6  ￿ 
101~  wt  EL4  cell  pellet.  Fractions  were  col- 
lected at 2-min intervals.  (B) Peptide specificity 
of CTL lines  and clones against  EL4 cells. The 
T  cell  line  C2D  and  clones  4D9,  1A7,  C12, 
C129, and 1B5 were tested  for cytolytic  activity 
on RMA-S cells pulsed with individual  HPLC 
fractions  from  either  K  b  or  D b.  Individual 
HPLC  fractions  were reconstituted in  200  I~1 
PBS and 1% aliquots used to pulse RMA-S tar- 
get cells as described  in Materials  and Methods. 
Fraction  6  represents the  pool of HPLC  frac- 
tions  1-6,  fractions  15,  16,  and  17  were col- 
lected  at 5-rain intervals.  E/T ratios used for as- 
says: (clone 4D9) 1:1;  (C2D line)  2:1;  (clone 
IA7)  1.5: 1; (clone  C12) 2:1;  (clone (:129) 2:1; 
and  (clone  IB5)  2:1.  The  unfractionated  K b- 
(m-/~) or Db- (m-/~) derived peptide pools at 
40  nM were also  used for pulsing of P,  MA-S 
cells to determine K  b or D b restriction of CTL 
clones. 
795  Johnston et al. Figure 4.  Recognition of tumor epitopes by BC-SC from mice immunized with B7 or B7 + EL4 cells. BC-SC from mice immunized with either B7- 
(A-C) or B7 + EL4 (C-E) were generated and tested for cytolytic activity on wt EL4 (A and D) and on RMA-S cells pulsed with individual HPLC frac- 
tions from either K  b (B and E) or D b (C and F). An E/T ratio of 40 : 1 was used in all experiments.  Three similar preparations of HPLC-purified peptides, 
quantitated  by serial dilution  using BC-SC or CTL clones in a 5tCr release assay, were used for all experiments  presented  in this report.  The results are 
expressed as the individual  (dot) and the mean (horizontal line) of percent SlCr release from RMA-S pulsed with peptides from 20 independent experi- 
ments with BC-SC from B7- EL4-immunized mice and 20 experiments  with SC from B7  + EL4-immunized mice. (Arrows) Fractions ofpeptide recog- 
nized by CTL clones (see Fig. 3 t3'). The background  SlCr release in the control group (incubation  of BC-SC with RMA-S cells and no peptides) was 
subtracted from counts of the experimental group. 
zation  with B7 +  EL4  cells activates  CTL  clones recogniz- 
ing not only immunodominant  but also subdominant  EL4 
antigens. 
These  findings  cannot  be  interpreted  on  the  basis  of a 
different expression level of MHC  class I  molecules in B7 + 
and  B7-  EL4  cells,  since  these  two  types  of cells  express 
similar  levels of K b  and  D b  molecules  as  determined  both 
by MHC  class I-peptide complex quantitation  and peptide 
purification  after  reversed-phase  HPLC  (data  not  shown) 
and  by  flow  cytometry  with  specific  mAbs  (24).  In  addi- 
tion,  there  are  no  quantitative  differences  in  the  lysis  of 
B7 +  and  B7-  EL4  cells by  either  BC-SC  or  CTL  clones 
(data  not  shown).  To  demonstrate  whether  B7 +  and  B7- 
EL4  cells  express  similar  levels  of antigenic  peptides,  we 
prepared peptides from both wt EL4 and B7 + EL4 cells and 
compared  their  ability  to  sensitize  RMA-S  for  lysis  by 
CTL. As shown,  fraction 9  of K b (Fig.  5  A), fraction 8  and 
9  of D b  (Fig.  5,  B  and  C)  prepared  from either wt EL4 or 
B7 +  EL4  cells  were  equally  efficient  on  sensitization  of 
RMA-S  cells for  CTL  lysis.  We  conclude  that  the  differ- 
ence in the ability of B7-  EL4 and B7 + EL4 cells to induce 
a  CTL  response  is  due  to  the  ability  of the  latter  cells  to 
provide B7-CD28  costimulation. 
In  Vivo Exposure to B7-  EL4 Cells Does Not Induce  Toler- 
ance/Anergy of CTL against  Subdominant Epitopes.  To  ex- 
amine  whether  subdominant  antigens  induce  tolerance  in 
vivo, we  first  injected  B7-  EL4  cells into  mice  to  induce 
tumor and then injected these mice with B7 + EL4 cells at a 
distant  site  either  at  the  same  time  or  1,  2,  3  wk  later. 
Growth  of tumor  nodules  induced  by  B7 +  EL4  cells was 
monitored  2-4  wk  after challenge with B7 §  EL4  cells.  As 
shown in Fig. 6, A-D, tumor nodules induced by B7 + EL4 
cells regressed  rapidly  in  all the  mice regardless  of the  size 
of the  B7-  EL4  tumor  they were  bearing,  indicating  that 
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Figure 5.  Comparison  between the ability of HPLC-fractionated  pep- 
tides from wt EL4 and  B7 + EL4  to sensitize RMA-S cells. Equivalent 
amounts  of HPLC-fractionated  peptides from either wt EL4 or B7 § EL4 
were prepared and used for pulsing RMA-S cells. The sensitivity of pep- 
tide-pulsed  cells was examined  by coculture  with 4D9 clone,  CD2 line, 
or the  BC-SC.  (A)  Cytolytic  activity  of 4D9  clone  on  RMA-S  cells 
pulsed with 1 ~1 of HPLC fraction 9 ofK  b. E/R ratio was t : 1. (13) Cy- 
totytic activity of C2D line on RMA-S cells pulsed with 1 ~1 of HPLC 
fraction  8 of D b. E/T ratio  was  10:1.  (C) Cytolytic  activity of BC-SC 
from a B7 + EL-4-immunized mouse on 1LMA-S cells pulsed with 1 ~1 of 
HPLC fraction 14 ofD  b. E/T ratio was 40: l. 
796  Cytolytic T  Lymphocyte Hierarchy and B7 Costimulation an immune response against EL4 cells is not affected by the 
tumor-beating status. 
The CTL activity against EL4 tumor in tumor-beating 
mice was also examined. There were no significant changes 
after challenge with B7 + EL4 cells in the CTL response of 
mice beating wt EL4 for 0, 1, or 2 wk (Fig. 6 E), although 
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a  significant  decrease  of CTL  activity was  seen  in  mice 
bearing large  3-wk  EL4 tumors.  Moreover,  several sub- 
dominant epitopes presented by both K  b (fraction 13) and 
D b (fractions 12,  13,  and 14) molecules can be recognized 
by BC-SC from mice beating wt EL4 for 2 wk followed by 
challenge with B7 + EL4 cells (Fig. 6 F). Since the CTL as- 
wt EL4 
B7  + EL4 
Figure 6.  CTL reactivity to B7 + EL4 cells in mice exposed to B7- EL4 
cells. C57BL/6 mice, in groups of 5, were injected with 5  ￿  104 wt EL4 
cells s.c. at 3, 2, and 1 wk before or at the same time and were then chal- 
lenged on the distant site with 5  X  104 B7 + EL4 cells. Tumor growth at 
both sites was assessed and is presented as mean minor diameters in D,  C, 
B, and A, respectively. (E  3  2  wk after injection of B7 + EL4 cells, spleen 
cells were prepared and cocultured with irradiated B7 §  EL4 for 5  d  after 
which BC-SC were tested for cytolytic activity on wt EL4 cells at a ratio 
80 : 1.  (F) BC-SC  from three mice immunized with wt EL4 at 2  wk be- 
fore challenge with B7 + EL4 cells were tested for CTL activity on RMA-S 
cells pulsed with 1 I~1 of HPLC-fmctionated peptides. 
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Figure 7.  Treatment of mice with EL4 ascites tumor by adoptive trans- 
fer  of  a  CTL  clone  specifically recognizing  a  subdominant  epitope. 
C57BL/6 mice, in groups of five, were injected with 104 wt EL4 cells i.p. 
3 d later, they were injected with 5 X 106 cells i.p. ofT cell clone C129 
followed the next day by injection with 1,500 U of IL-2 i.p.; injection of 
IL-2 was repeated once a day for three consecutive  days. Control groups 
were injected with  IL-2 combined with  a control  (C57BL/6 against 
H-2  a) CTL line. The mice were monitored daily for survival and the ex- 
periment was terminated at day 100 after tumor inoculation. 
says in Fig. 4 were all performed 2 wk after injection ofwt 
EL4,  we conclude that  the  absence  of a  CTL response  to 
subdominant EL4 epitopes  was not caused by CTL toler- 
ance or anergy in mice beating wt EL4 tumor. 
Treatment  of EL4 Ascites  Tumor by Adoptive  Transfer of a 
CTL Clone Recognizing  a Subdominant  Tumor Epitope.  To 
determine  whether  a  CTL  clone  recognizing a  subdomi- 
nant  epitope  can be  employed for treatment  of an  estab- 
lished EL4 tumor, we treated C57BL/6 mice that had been 
injected intraperitoneally with wt EL4 cells  3  d previously 
and had EL4 growing as an ascites tumor. Two of five mice 
treated with the CTL clone C129 plus IL-2 died at days 31 
and 78 without visible ascites, whereas the three remaining 
mice were  alive without  sign  of tumor when  the  experi- 
ment was terminated on day 100 (Fig. 7). In contrast, mice 
treated with IL-2 combined with a control anti-H-2 d CTL 
line all died with ascites within 40 d of tumor cell injection. 
Discussion 
We  have  demonstrated  that  at  least  six  distinct  tumor 
peptides are processed and presented by MHC class I mole- 
cules  of the  EL4 lymphoma cells in such a  way that they 
can serve as targets for recognition by CTL clones in vitro 
and/or  in  vivo.  However,  the  majority  of  these  CTL 
epitopes are silent, i.e., they fail to induce an efficient CTL 
response unless the B7-1 gene has been transfected into the 
EL4  tumor used  as  immunogen.  They are,  therefore,  re- 
ferred  to  as  subdominant.  Our findings  thus  indicate  that 
even when a tumor expresses a multitude  of potential tar- 
get epitopes, and is able to present them, its immunogenic- 
ity may still be low. 
One may speculate that exposure of CTL to tumor anti- 
gens presented  by a  B7-negative  tumor,  such  as  the  EL4 
lymphoma,  may induce  antigen-specific  tolerance.  In  the 
present  study,  however,  several  lines  of evidence  do  not 
support this mechanism: (a) mice bearing a large EL4 lym- 
phoma were resistant  to challenge with B7 + EL4 cells  (2, 
and Fig. 6, A-D); (b) the CTL activity which could be in- 
duced by immunization with B7 + EL4 cells was not signif- 
icantly  affected  until  after  3  wk  of tumor-beating  status 
(Fig. 6 E); and (c) the BC-SC from mice bearing 2-wk-old 
EL4 tumor could still react to several subdominant epitopes 
(Fig.  6  F). Although a single injection of B7 + EL4 cells is 
not sufficient to induce regression of established large EL4 
tumors (Fig. 6, A-D), small tumors can be cured ifmnltiple 
injections of B7 + EL4 cells  are initiated at an early stage of 
tumor growth (24).  It is noteworthy that signaling through 
the B7-CD28 pathway has been shown to prevent the in- 
duction  of T  cell anergy in vitro  (22,  23)  whereas  it does 
not break already formed T  cell anergy (2, 5). Our findings 
thus  indicate  that  there  was no T  cell  tolerance/anergy  at 
least during the first 2 wk of growth ofwt EL4 tumor. 
The requirements  for sensitizing a target cell for lysis by 
an  already  activated  CTL  clone  and  for  activating  CTL 
clones in a naive animal are different with presentation  of 
much more antigenic peptides  being required  in the latter 
case (34-36).  It is thus possible that CTL clones "ignore" a 
peptide encoding a tumor antigen unless it is expressed at a 
certain level needed for activation. EL4 cells are capable of 
presenting  subdominant  epitopes  (Fig.  3)  but  probably  at 
low level.  It is possible that one of the roles of costimula- 
tion mediated by B7-1 is to decrease such a nfinimal "thresh- 
old" requirement for antigenic peptides to activate CTL. 
Our findings have several implications for the immuno- 
therapy of cancers.  Whereas a  tumor can express  multiple 
antigens  recognized by CTL simultaneously,  the  CTL re- 
sponse to tumor usually is directed to one or, at best, a few 
antigens, a situation that may facilitate the selection of anti- 
gen-negative escape variants  (12,  37, 38).  We have shown 
that immunization with a tumor engineered to express B7 
can  stimulate  multiple  CTL  clonal  expansions  against  an 
expanded array of antigens, and this should make tumor es- 
cape less  likely.  The generation  of CTL against subdomi- 
nant antigens will also offer opportunities to explore novel 
targets for T  cell-mediated cancer therapy. 
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